Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.

Overall, ORRs were markedly more favourable for trametinib than standard-of-care therapy in mutation-positive patients (11 [50%] of 22 vs two [9%] of 22) than in mutation-negative patients (four [8%] of 48 vs three [7%] of 42), although this did not reach statistical significance (multiple comparison adjusted p=0·11, test for interaction).

also in 111,027 other papers

Trametinib was also associated with a four-fold increase in the probability of response to therapy, and showed a trend toward an overall survival benefit, despite the 68% of patients in the standard-of care group who crossed over to trametinib.

also in 53,322 other papers